

# Ningetinib

## Catalog No: tcsc0027542

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Dimensional Sizes

Permula:

 $\mathsf{C_{31}H_{29}FN_4O_5}$ 

**Pathway:** Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

#### Target: c-Met/HGFR;VEGFR;TAM Receptor

#### Purity / Grade:

>98%

#### Solubility:

10 mM in DMSO

#### **Observed Molecular Weight:**

556.58

Copyright 2021 Taiclone Biotech Corp.




### **Product Description**

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with **IC**<sub>50</sub>s of 6.7, 1.9 and c-Met, **VEGFR2** and **AxI**, respectively.

IC50 & Target: VEGFR, c-Met, and Axl<sup>[1]</sup>

*In Vitro:* Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC<sub>50</sub>s of 6.7, 1.9 and 50 values of 8.6 and 6.3 nM, respectively<sup>[1]</sup>.

*In Vivo:* When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib (CT053PTSA) potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues. In orthotopic U87MG human glioblastoma xenograft model, Ningetinib prolongs the median survival time (MST) and yields significant increase in life-span value (ILS=32%, p=0.003) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.